secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-046055
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics reports FY2024 net loss $41.8M, cash $30.3M; amezalpat gets FDA designations
--------------------------------------------------------------------------------

- Net loss $41.8M ($1.50/share) vs $29.5M ($1.91/share) in 2023; R&D spend rose to $28.5M.
- Cash and equivalents $30.3M at Dec 31, 2024, down from $39.2M; ATM proceeds of $28.6M partially offset burn.
- Amezalpat (TPST-1120) received FDA Orphan Drug and Fast Track status for first-line HCC.
- Agreement signed with Roche to support pivotal Phase 3 trial of amezalpat + atezolizumab + bevacizumab in HCC.
- FDA cleared Phase 2 trial of TPST-1495 for familial adenomatous polyposis; data expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000095017025046055/0000950170-25-046055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000095017025046055/tpst-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer